Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Reexamination Certificate
2011-04-05
2011-04-05
Kim, Jennifer M (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
C424S482000, C424S457000, C424S458000, C424S455000, C424S474000, C424S495000, C424S497000, C424S489000, C424S498000, C424S490000
Reexamination Certificate
active
07919483
ABSTRACT:
A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
REFERENCES:
patent: 3932615 (1976-01-01), Ito et al.
patent: 3957980 (1976-05-01), Noseworthy
patent: 3966922 (1976-06-01), Okamoto et al.
patent: 4086332 (1978-04-01), Armstrong
patent: 4126680 (1978-11-01), Armstrong
patent: 4369172 (1983-01-01), Schor et al.
patent: 4376118 (1983-03-01), Daher et al.
patent: 4443442 (1984-04-01), Skillern
patent: 4701320 (1987-10-01), Hasegawa et al.
patent: 4764377 (1988-08-01), Goodson
patent: 4792448 (1988-12-01), Ranade
patent: 4806529 (1989-02-01), Levy
patent: 4837030 (1989-06-01), Valorose, Jr. et al.
patent: 4925833 (1990-05-01), McNamara et al.
patent: 4935411 (1990-06-01), McNamara et al.
patent: 4935412 (1990-06-01), McNamara et al.
patent: 4960913 (1990-10-01), Szalay et al.
patent: 5007790 (1991-04-01), Shell
patent: 5122519 (1992-06-01), Ritter
patent: 5167964 (1992-12-01), Muhammad et al.
patent: 5188836 (1993-02-01), Muhammad et al.
patent: 5202128 (1993-04-01), Morella et al.
patent: 5209978 (1993-05-01), Kosaka et al.
patent: 5211958 (1993-05-01), Akkerboom et al.
patent: 5217493 (1993-06-01), Raad et al.
patent: 5230895 (1993-07-01), Czarnecki et al.
patent: 5262173 (1993-11-01), Sheth et al.
patent: 5277916 (1994-01-01), Dwyer et al.
patent: 5283065 (1994-02-01), Doyon et al.
patent: 5300304 (1994-04-01), Sheth et al.
patent: 5324751 (1994-06-01), DuRoss
patent: 5348748 (1994-09-01), Sheth et al.
patent: 5413777 (1995-05-01), Sheth et al.
patent: 5459135 (1995-10-01), Golub et al.
patent: 5518730 (1996-05-01), Fuisz
patent: 5554654 (1996-09-01), Yu et al.
patent: 5582837 (1996-12-01), Shell
patent: 5665776 (1997-09-01), Yu et al.
patent: 5674539 (1997-10-01), Tomas
patent: 5776489 (1998-07-01), Preston et al.
patent: 5780049 (1998-07-01), Dickner et al.
patent: 5800836 (1998-09-01), Morella et al.
patent: 5814331 (1998-09-01), Holen
patent: 5834450 (1998-11-01), Su
patent: 5855904 (1999-01-01), Chung et al.
patent: 5908838 (1999-06-01), Gans
patent: 5972389 (1999-10-01), Shell et al.
patent: 6087382 (2000-07-01), Bonner, Jr. et al.
patent: 6120803 (2000-09-01), Wong et al.
patent: 6165513 (2000-12-01), Dansereau et al.
patent: 6165999 (2000-12-01), Vu
patent: 6194000 (2001-02-01), Smith et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 6340476 (2002-01-01), Midha et al.
patent: 6429204 (2002-08-01), Golub et al.
patent: 6455583 (2002-09-01), Pflugfelder et al.
patent: 6497902 (2002-12-01), Ma
patent: 6638922 (2003-10-01), Ashley et al.
patent: 6673843 (2004-01-01), Arbiser
patent: 6863830 (2005-03-01), Purdy et al.
patent: 6958161 (2005-10-01), Hayes et al.
patent: 7008631 (2006-03-01), Ashley
patent: 7211267 (2007-05-01), Ashley
patent: 2002/0015731 (2002-02-01), Appel et al.
patent: 2003/0082120 (2003-05-01), Milstein
patent: 2003/0130240 (2003-07-01), Ashley
patent: 2003/0139380 (2003-07-01), Ashley
patent: 2003/0199480 (2003-10-01), Hayes et al.
patent: 2003/0229055 (2003-12-01), Ashley
patent: 2004/0002481 (2004-01-01), Ashley et al.
patent: 2004/0115261 (2004-06-01), Ashley
patent: 2004/0127471 (2004-07-01), Reisberg
patent: 2004/0228912 (2004-11-01), Chang et al.
patent: 2005/0136107 (2005-06-01), Patel et al.
patent: 2005/0148552 (2005-07-01), Ryan et al.
patent: 2006/0293290 (2006-12-01), Wortzman et al.
patent: 2025703 (1990-09-01), None
patent: 2068366 (1992-11-01), None
patent: 2090561 (1993-02-01), None
patent: 0 184 389 (1986-06-01), None
patent: 0 418 565 (1991-03-01), None
patent: 0 558 913 (1992-09-01), None
patent: 2414668 (2005-12-01), None
patent: WO 93/18755 (1993-09-01), None
patent: WO 98/11879 (1998-03-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 02/080932 (2002-10-01), None
patent: WO 03/088906 (2003-10-01), None
patent: WO 2004/012700 (2004-02-01), None
patent: WO 2004/078111 (2004-09-01), None
American Hospital Formulary SErvice Drug Information 88, 1988, pp. 330-331.
Gans et al. The Solubility and Complexing properties of Oxytetracycline and Tetracycline II, Journal of the American Pharmaceutical Association, Sci. Ed. 46, No. 10, Oct. 1957.
AAI International PROCORE® Technology, referencing patents issued prior to 2000.
AAI International PROSLO™ and PROSLO™ II Tablets Technology, referencing patents issued prior to 2000.
AAI International PROSORB® Technology, referencing patents issued prior to 2000.
Sheehan-Dare, et al., “A Double-blind Comparison of Topical Clindamycin and Oral Minocyclin in the Treatment of Acne Vulgaris”, Acta Derm Venereol (Stockh), 70, pp. 534-537, 1990.
Solodyn (Minocycline HCl Extended Release Tablets) Labeling and package insert information, submitted with a New Drug Application approved May 8, 2006.
Gollnick, Harald, et al., “Management of Acne, A Report From a Global Alliance to Improve Outcomes in Acne”, Supplement to Journal of The American Academy of Dermatology, Jul. 2003, vol. 49, No. 1, S1-37.
Leyden, James, J., “Absorption of minocycline hydrochloride and tetracycline hydrochloride”, J. Am. Acad. Dermatol. 12:308-312, 1985.
Smith, Kelly, et al., “Safety of Doxycycline and Minocycline: A Systematic Review”, Clinical Therapeutics, The International Peer-Reviewed Journal of Drug Therapy, vol. 27, No. 9, Sep. 2005, 1329-1342.
Leyden, James J., et al., “Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris”, Archives of Dermatology, May 2006, 605-612.
Leyden, James J, et al., “The antimicrobial effects in vivo of minocycline, doxycycline and tetracycline in humans”, The Journal of Dermatological Treatment, Dec. 1996, vol. 7, No. 4, 223-225.
Leyden, James J., et al., “Tetracycline and Minocycline Treatment, Effects on Skin-Surface Lipid Levels andPropionibacterium acnes”, Archives of Dermatology, 1982, vol. 118, 19-22.
Leyden, James J., et al., “Pseudomonas aeruginosaGram-Negative Folliculitis”, Archives of Dermatology, 1979, vol. 115, 1203-1204.
Leyden, James J., et al., “Clinical Considerations in the Treatment of Acne Vulgaris and Other Inflammatory Skin Disorders: Focus on Antibiotic Resistance”, Cutis 2007 (suppl. 6), vol. 79, No. 65, 9-25.
Marks, Ronald, et al., (eds.) “Dermatologic Therapy in Current Practice”, Chapter 3, 35-44 (2002).
International Search Report and Written Opinion mailed Dec. 5, 2007 pp. 1-18.
Office Communication dated Jun. 25, 2009 in U.S. Appl. No. 11/776,669.
Office Communication dated Jun. 10, 2009 in U.S. Appl. No. 11/776,676.
Office Communication dated May 29, 2009 in U.S. Appl. No. 11/776,711.
Office Communication dated May 29, 2009 in U.S. Appl. No. 11/944,186.
Office Communication dated Jun. 10, 2009 in U.S. Appl. No. 11/695,514.
Drugs.com, Drug information online, Minocin PAC product information, Aug. 2007.
Minocin Product Insert, Wyeth Pharmaceuticals Inc. Rev 10/05.
Prescribingreference.com, Prescribing Reference, Drug News—Minocin PAC for Acne (Oct. 11, 2006).
Physician's Desk Reference; MINOCIN®: Minocycline Hydrochloride for Oral Use; Physician's Desk Reference, 1989, pp. 1134-1136, 43rd Edition; Edward R. Barnhard, publisher, Medical Economics Co., Inc.; Oradell, NJ.
Office Communication dated Nov. 6, 2007 in U.S. Appl. No. 11/776,669.
Office Communication dated Jun. 17, 2008 in U.S. Appl. No. 11/776,669.
Office Communication dated Dec. 1, 2008 in U.S. Appl. No. 11/776,669.
Office Communication dated Nov. 6, 2007 in U.S. Appl. No. 11/776,676.
Office Communication dated Aug. 8, 2008 in U.S. Appl. No. 11/776,676.
Office Communication dated Nov. 6, 2007 in U.S. Appl. No. 11/776,711.
Office Communication dated Jun. 17, 2008 in U.S. Appl. No. 11/776,711.
Office Communication dated Nov. 17, 2008 in U.S. Appl. No. 11/944,186.
Office Communication dated Dec. 24, 2008 in U.S. Appl. No. 11/695,514.
Office Communication dated Jul. 22, 2008 in U.S. Appl. No. 11/695,528.
Office Communication dated Jul. 23, 2008 in U.S. Appl. No. 11/695,539.
Office Commun
Bhatia Kuljit
Patel Bhiku
Plott R. Todd
Wortzman Mitchell
Kim Jennifer M
Medicis Pharmaceutical Corporation
Ohlandt Greeley Ruggiero & Perle L.L.P.
LandOfFree
Method for the treatment of acne does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of acne, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of acne will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715884